BIOLINERX
Careers | Contact Us
search

Press Releases
September 17, 2014
Results in this additional indication for BL-8040 presented at Society of Hematologic Oncology (SOHO) Annual Meeting
BL-8040 also undergoing Phase 2 study in AML, with final results expected in early 2015; and Phase 1 study in stem cell mobilization, with results expected by year-end 2014 or early 2015 

September 3, 2014
Results from Phase 1 trial expected by end of 2014 or early 2015
BL-8040 also in midst of Phase 2 trial for AML, with results expected in early 2015
August 21, 2014
BL-7010 for treatment of celiac disease is currently in final stages of Phase 1/2 safety study; efficacy study expected to commence in early 2015
July 30, 2014
Management to hold a conference call at 10:00 a.m. EDT
July 16, 2014
BL-7010 well tolerated in both single- and repeated-dose administrations
Supports classification as medical device in Europe due to lack of systemic absorption
Company to investigate lower doses of BL-7010 prior to commencing efficacy study expected in early 2015

June 23, 2014
BL-1110 was shown in preclinical studies to enhance analgesic effect of morphine while reducing negative side effects 
BL-1110 may also be developed for scleroderma

June 16, 2014
Phase 1 trial of BL-8040 expected to begin in Q3 2014; results expected in late 2014 or early 2015
BL-8040 also in Phase 2 for AML; results expected in early 2015

June 11, 2014
Results of ongoing Phase 1/2 trial for BL-7010 expected in next few weeks
151-160  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next